Quilter Plc Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Quilter Plc raised its position in Amgen Inc. (NASDAQ:AMGN) by 1.4% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 3,749 shares of the medical research company’s stock after purchasing an additional 50 shares during the period. Quilter Plc’s holdings in Amgen were worth $1,171,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Aveo Capital Partners LLC raised its stake in shares of Amgen by 19.9% during the 4th quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock worth $786,000 after purchasing an additional 453 shares during the period. Gryphon Financial Partners LLC raised its position in Amgen by 295.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock worth $1,021,000 after acquiring an additional 2,752 shares during the period. Level Four Advisory Services LLC boosted its stake in Amgen by 2.6% in the fourth quarter. Level Four Advisory Services LLC now owns 3,958 shares of the medical research company’s stock valued at $1,140,000 after acquiring an additional 100 shares during the last quarter. MainStreet Investment Advisors LLC grew its position in shares of Amgen by 5.1% during the 4th quarter. MainStreet Investment Advisors LLC now owns 3,256 shares of the medical research company’s stock valued at $938,000 after acquiring an additional 158 shares during the period. Finally, Hillsdale Investment Management Inc. increased its stake in shares of Amgen by 49.2% during the 4th quarter. Hillsdale Investment Management Inc. now owns 970 shares of the medical research company’s stock worth $279,000 after purchasing an additional 320 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.7 %

Shares of AMGN stock opened at $332.45 on Monday. The company has a market capitalization of $178.64 billion, a PE ratio of 47.49, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The business’s fifty day moving average is $328.18 and its 200 day moving average is $304.00. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the business earned $5.00 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on AMGN shares. Bank of America upped their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Argus upped their price target on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Morgan Stanley decreased their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada increased their target price on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.